Pleural mesothelioma classification update

Abstract

The 2015 WHO classification of pleural mesotheliomas includes three major histologic subtypes—epithelioid, sarcomatoid, and biphasic. Recent genomic data has supported the need for a more granular and clinically valid classification beyond the three current subtypes. Because of tumor rarity and overlapping histologic features with other tumor types, diagnostic immunohistochemical work up is essential component in establishing the final diagnosis of mesothelioma. The use of BAP1 and CDKN2A/MTAP improves the diagnostic sensitivity of effusion specimens and are valuable in establishing the diagnosis of epithelioid mesothelioma. The major change in the forthcoming WHO classification is the inclusion of mesothelioma in situ as a diagnostic category. In this review, we discuss recently proposed changes in the histologic classification of pleural mesothelioma, differential diagnosis, and importance of ancillary diagnostic studies.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9
Fig. 10
Fig. 11
Fig. 12
Fig. 13

References

  1. 1.

    Ahadi MS, Gill AJ (2019) SMARCA4 loss is very rare in thoracic mesothelioma. Am J Surg Pathol 43:1154–1155. https://doi.org/10.1097/PAS.0000000000001262

    Article  PubMed  Google Scholar 

  2. 2.

    Alchami FS, Attanoos RL, Bamber AR (2017) Myxoid variant epithelioid pleural mesothelioma defines a favourable prognosis group: an analysis of 191 patients with pleural malignant mesothelioma. J Clin Pathol 70:179–182. https://doi.org/10.1136/jclinpath-2016-203993

    Article  PubMed  Google Scholar 

  3. 3.

    Andrici J, Sheen A, Sioson L, Wardell K, Clarkson A, Watson N, Ahadi MS, Farzin M, Toon CW, Gill AJ (2015) Loss of expression of BAP1 is a useful adjunct, which strongly supports the diagnosis of mesothelioma in effusion cytology. Mod Pathol 28:1360–1368. https://doi.org/10.1038/modpathol.2015.87

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  4. 4.

    Arif Q, Husain AN (2015) Malignant mesothelioma diagnosis. Arch Pathol Lab Med 139:978–980. https://doi.org/10.5858/arpa.2013-0381-RA

    CAS  Article  PubMed  Google Scholar 

  5. 5.

    Attanoos RL, Pugh MR (2018) The diagnosis of pleural tumors other than mesothelioma. Arch Pathol Lab Med 142:902–913. https://doi.org/10.5858/arpa.2017-0537-RA

    Article  PubMed  Google Scholar 

  6. 6.

    Berg KB, Churg A (2017) GATA3 Immunohistochemistry for distinguishing sarcomatoid and desmoplastic mesothelioma from sarcomatoid carcinoma of the lung. Am J Surg Pathol 41:1221–1225. https://doi.org/10.1097/PAS.0000000000000825

    Article  PubMed  Google Scholar 

  7. 7.

    Berg KB, Dacic S, Miller C, Cheung S, Churg A (2018) Utility of methylthioadenosine phosphorylase compared with BAP1 immunohistochemistry, and CDKN2A and NF2 fluorescence in situ hybridization in separating reactive mesothelial proliferations from epithelioid malignant mesotheliomas. Arch Pathol Lab Med 142:1549–1553. https://doi.org/10.5858/arpa.2018-0273-OA

    CAS  Article  PubMed  Google Scholar 

  8. 8.

    Berg KB, Churg AM, Cheung S, Dacic S (2020) Usefulness of methylthioadenosine phosphorylase and BRCA-associated protein 1 immunohistochemistry in the diagnosis of malignant mesothelioma in effusion cytology specimens. Cancer Cytopathol 128:126–132. https://doi.org/10.1002/cncy.22221

    CAS  Article  PubMed  Google Scholar 

  9. 9.

    Bilecz A, Stockhammer P, Theegarten D, Kern I, Jakopovic M, Samarzija M, Klikovits T, Hoda MA, Dome B, Oberndorfer F, Muellauer L, Fillinger J, Kovacs I, Pirker C, Schuler M, Plones T, Aigner C, Klepetko W, Berger W, Brcic L, Laszlo V, Hegedus B (2020) Comparative analysis of prognostic histopathologic parameters in subtypes of epithelioid pleural mesothelioma. Histopathology 77:55–66. https://doi.org/10.1111/his.14105

    Article  PubMed  Google Scholar 

  10. 10.

    Bonk S, Kluth M, Hube-Magg C, Polonski A, Soekeland G, Makropidi-Fraune G, Moller-Koop C, Witt M, Luebke AM, Hinsch A, Burandt E, Steurer S, Clauditz TS, Schlomm T, Perez D, Graefen M, Heinzer H, Huland H, Izbicki JR, Wilczak W, Minner S, Sauter G, Simon R (2019) Prognostic and diagnostic role of PSA immunohistochemistry: a tissue microarray study on 21,000 normal and cancerous tissues. Oncotarget 10:5439–5453. https://doi.org/10.18632/oncotarget.27145

    Article  PubMed  PubMed Central  Google Scholar 

  11. 11.

    Brcic L, Vlacic G, Quehenberger F, Kern I (2018) Reproducibility of malignant pleural mesothelioma histopathologic subtyping. Arch Pathol Lab Med 142:747–752. https://doi.org/10.5858/arpa.2017-0295-OA

    Article  PubMed  Google Scholar 

  12. 12.

    Butnor KJ, Nicholson AG, Allred DC, Zander DS, Henderson DW, Barrios R, Haque AK, Allen TC, Killen DE, Cagle PT (2006) Expression of renal cell carcinoma-associated markers erythropoietin, CD10, and renal cell carcinoma marker in diffuse malignant mesothelioma and metastatic renal cell carcinoma. Arch Pathol Lab Med 130:823–827. https://doi.org/10.1043/1543-2165(2006)130[823:EORCCM]2.0.CO;2

    CAS  Article  PubMed  Google Scholar 

  13. 13.

    Chapel DB, Husain AN, Krausz T, McGregor SM (2017) PAX8 expression in a subset of malignant peritoneal mesotheliomas and benign mesothelium has diagnostic implications in the differential diagnosis of ovarian serous carcinoma. Am J Surg Pathol 41:1675–1682. https://doi.org/10.1097/PAS.0000000000000935

    Article  PubMed  Google Scholar 

  14. 14.

    Chevrier M, Monaco SE, Jerome JA, Galateau-Salle F, Churg A, Dacic S (2020) Testing for BAP1 loss and CDKN2A/p16 homozygous deletion improves the accurate diagnosis of mesothelial proliferations in effusion cytology. Cancer Cytopathol 128:939–947. https://doi.org/10.1002/cncy.22326

    CAS  Article  PubMed  Google Scholar 

  15. 15.

    Chiosea S, Krasinskas A, Cagle PT, Mitchell KA, Zander DS, Dacic S (2008) Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas. Mod Pathol 21:742–747. https://doi.org/10.1038/modpathol.2008.45

    CAS  Article  PubMed  Google Scholar 

  16. 16.

    Chung LS, Man YG, Lupton GP (2010) WT-1 expression in a spectrum of melanocytic lesions: implication for differential diagnosis. J Cancer 1:120–125. https://doi.org/10.7150/jca.1.120

    Article  PubMed  PubMed Central  Google Scholar 

  17. 17.

    Churg A, Cagle P, Colby TV, Corson JM, Gibbs AR, Hammar S, Ordonez N, Roggli VL, Tazelaar HD, Travis WD, Wick M, Panel US-CMR (2011) The fake fat phenomenon in organizing pleuritis: a source of confusion with desmoplastic malignant mesotheliomas. Am J Surg Pathol 35:1823–1829. https://doi.org/10.1097/PAS.0b013e31822a2481

    Article  Google Scholar 

  18. 18.

    Churg A, Galateau-Salle F (2012) The separation of benign and malignant mesothelial proliferations. Arch Pathol Lab Med 136:1217–1226. https://doi.org/10.5858/arpa.2012-0112-RA

    Article  PubMed  Google Scholar 

  19. 19.

    Churg A, Colby TV, Cagle P, Corson J, Gibbs AR, Gilks B, Grimes M, Hammar S, Roggli V, Travis WD (2000) The separation of benign and malignant mesothelial proliferations. Am J Surg Pathol 24:1183–1200

    CAS  Article  Google Scholar 

  20. 20.

    Churg A, Hwang H, Tan L, Qing G, Taher A, Tong A, Bilawich AM, Dacic S (2018) Malignant mesothelioma in situ. Histopathology 72:1033–1038. https://doi.org/10.1111/his.13468

    Article  PubMed  Google Scholar 

  21. 21.

    Churg A, Galateau-Salle F, Roden AC, Attanoos R, von der Thusen JH, Tsao MS, Chang N, De Perrot M, Dacic S (2020) Malignant mesothelioma in situ: morphologic features and clinical outcome. Mod Pathol 33:297–302. https://doi.org/10.1038/s41379-019-0347-0

    CAS  Article  PubMed  Google Scholar 

  22. 22.

    Cigognetti M, Lonardi S, Fisogni S, Balzarini P, Pellegrini V, Tironi A, Bercich L, Bugatti M, Rossi G, Murer B, Barbareschi M, Giuliani S, Cavazza A, Marchetti G, Vermi W, Facchetti F (2015) BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations. Mod Pathol 28:1043–1057. https://doi.org/10.1038/modpathol.2015.65

    CAS  Article  PubMed  Google Scholar 

  23. 23.

    Cozzi I, Oprescu FA, Rullo E, Ascoli V (2018) Loss of BRCA1-associated protein 1 (BAP1) expression is useful in diagnostic cytopathology of malignant mesothelioma in effusions. Diagn Cytopathol 46:9–14. https://doi.org/10.1002/dc.23837

    Article  PubMed  Google Scholar 

  24. 24.

    Dacic S, Le Stang N, Husain A, Weynand B, Beasley MB, Butnor K, Chapel D, Gibbs A, Klebe S, Lantuejoul S, Roden AC, Roggli V, Tazelaar H, Vignaud JM, Galateau-Salle F (2020) Interobserver variation in the assessment of the sarcomatoid and transitional components in biphasic mesotheliomas. Mod Pathol 33:255–262. https://doi.org/10.1038/s41379-019-0320-y

    CAS  Article  PubMed  Google Scholar 

  25. 25.

    Davidson B, Totsch M, Wohlschlaeger J, Hager T, Pinamonti M (2018) The diagnostic role of BAP1 in serous effusions. Hum Pathol 79:122–126. https://doi.org/10.1016/j.humpath.2018.05.012

    CAS  Article  PubMed  Google Scholar 

  26. 26.

    Fea G-S (2015) Tumors of the pleura. In: Travis WDBE, Burke AP, Marx A, Nicholson AG (eds) WHO Classification of tumors of the lung, pleura, thymus and heart. IARC Press, Lyon, pp 128–135

    Google Scholar 

  27. 27.

    Galateau Salle F, Le Stang N, Nicholson AG, Pissaloux D, Churg A, Klebe S, Roggli VL, Tazelaar HD, Vignaud JM, Attanoos R, Beasley MB, Begueret H, Capron F, Chirieac L, Copin MC, Dacic S, Danel C, Foulet-Roge A, Gibbs A, Giusiano-Courcambeck S, Hiroshima K, Hofman V, Husain AN, Kerr K, Marchevsky A, Nabeshima K, Picquenot JM, Rouquette I, Sagan C, Sauter JL, Thivolet F, Travis WD, Tsao MS, Weynand B, Damiola F, Scherpereel A, Pairon JC, Lantuejoul S, Rusch V, Girard N (2018) New insights on diagnostic reproducibility of biphasic mesotheliomas: a multi-institutional evaluation by the international mesothelioma panel from the MESOPATH reference center. J Thorac Oncol 13:1189–1203. https://doi.org/10.1016/j.jtho.2018.04.023

    CAS  Article  PubMed  Google Scholar 

  28. 28.

    Galateau Salle F, Le Stang N, Tirode F, Courtiol P, Nicholson AG, Tsao MS, Tazelaar HD, Churg A, Dacic S, Roggli V, Pissaloux D, Maussion C, Moarii M, Beasley MB, Begueret H, Chapel DB, Copin MC, Gibbs AR, Klebe S, Lantuejoul S, Nabeshima K, Vignaud JM, Attanoos R, Brcic L, Capron F, Chirieac LR, Damiola F, Sequeiros R, Cazes A, Damotte D, Foulet A, Giusiano-Courcambeck S, Hiroshima K, Hofman V, Husain AN, Kerr K, Marchevsky A, Paindavoine S, Picquenot JM, Rouquette I, Sagan C, Sauter J, Thivolet F, Brevet M, Rouvier P, Travis WD, Planchard G, Weynand B, Clozel T, Wainrib G, Fernandez-Cuesta L, Pairon JC, Rusch V, Girard N (2020) Comprehensive molecular and pathologic evaluation of transitional mesothelioma assisted by deep learning approach: a multi-institutional study of the international mesothelioma panel from the MESOPATH reference center. J Thorac Oncol 15:1037–1053. https://doi.org/10.1016/j.jtho.2020.01.025

    CAS  Article  PubMed  Google Scholar 

  29. 29.

    Galateau-Salle F, Churg A, Roggli V, Travis WD, World Health Organization Committee for Tumors of the P (2016) The 2015 World Health Organization classification of tumors of the pleura: advances since the 2004 classification. J Thorac Oncol 11:142–154. https://doi.org/10.1016/j.jtho.2015.11.005

    Article  Google Scholar 

  30. 30.

    Galateau-Salle F, Attanoos R, Gibbs AR, Burke L, Astoul P, Rolland P, Ilg AG, Pairon JC, Brochard P, Begueret H, Vignaud JM, Kerr K, Launoy G, Imbernon E, Goldberg M (2007) Lymphohistiocytoid variant of malignant mesothelioma of the pleura: a series of 22 cases. Am J Surg Pathol 31:711–716. https://doi.org/10.1097/PAS.0b013e31802baad7

    Article  PubMed  Google Scholar 

  31. 31.

    Garrido-Ruiz MC, Rodriguez-Pinilla SM, Perez-Gomez B, Rodriguez-Peralto JL (2010) WT 1 expression in nevi and melanomas: a marker of melanocytic invasion into the dermis. J Cutan Pathol 37:542–548. https://doi.org/10.1111/j.1600-0560.2009.01379.x

    CAS  Article  PubMed  Google Scholar 

  32. 32.

    Henderson DW, Attwood HD, Constance TJ, Shilkin KB, Steele RH (1988) Lymphohistiocytoid mesothelioma: a rare lymphomatoid variant of predominantly sarcomatoid mesothelioma. Ultrastruct Pathol 12:367–384. https://doi.org/10.3109/01913128809064207

    CAS  Article  PubMed  Google Scholar 

  33. 33.

    Henderson DW, Shilkin KB, Whitaker D (1998) Reactive mesothelial hyperplasia vs mesothelioma, including mesothelioma in situ: a brief review. Am J Clin Pathol 110:397–404. https://doi.org/10.1093/ajcp/110.3.397

    CAS  Article  PubMed  Google Scholar 

  34. 34.

    Hida T, Hamasaki M, Matsumoto S, Sato A, Tsujimura T, Kawahara K, Iwasaki A, Okamoto T, Oda Y, Honda H, Nabeshima K (2017) Immunohistochemical detection of MTAP and BAP1 protein loss for mesothelioma diagnosis: comparison with 9p21 FISH and BAP1 immunohistochemistry. Lung Cancer 104:98–105. https://doi.org/10.1016/j.lungcan.2016.12.017

    Article  PubMed  Google Scholar 

  35. 35.

    Husain AN, Colby TV, Ordonez NG, Allen TC, Attanoos RL, Beasley MB, Butnor KJ, Chirieac LR, Churg AM, Dacic S, Galateau-Salle F, Gibbs A, Gown AM, Krausz T, Litzky LA, Marchevsky A, Nicholson AG, Roggli VL, Sharma AK, Travis WD, Walts AE, Wick MR (2018) Guidelines for pathologic diagnosis of malignant mesothelioma 2017 update of the consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med 142:89–108. https://doi.org/10.5858/arpa.2017-0124-RA

    CAS  Article  PubMed  Google Scholar 

  36. 36.

    Hwang HC, Sheffield BS, Rodriguez S, Thompson K, Tse CH, Gown AM, Churg A (2016) Utility of BAP1 immunohistochemistry and p16 (CDKN2A) FISH in the diagnosis of malignant mesothelioma in effusion cytology specimens. Am J Surg Pathol 40:120–126. https://doi.org/10.1097/PAS.0000000000000529

    Article  PubMed  Google Scholar 

  37. 37.

    Kadota K, Suzuki K, Sima CS, Rusch VW, Adusumilli PS, Travis WD (2011) Pleomorphic epithelioid diffuse malignant pleural mesothelioma: a clinicopathological review and conceptual proposal to reclassify as biphasic or sarcomatoid mesothelioma. J Thorac Oncol 6:896–904. https://doi.org/10.1097/JTO.0b013e318211127a

    Article  PubMed  Google Scholar 

  38. 38.

    Kadota K, Suzuki K, Colovos C, Sima CS, Rusch VW, Travis WD, Adusumilli PS (2012) A nuclear grading system is a strong predictor of survival in epitheloid diffuse malignant pleural mesothelioma. Mod Pathol 25:260–271. https://doi.org/10.1038/modpathol.2011.146

    CAS  Article  PubMed  Google Scholar 

  39. 39.

    Karavitakis EM, Moschovi M, Stefanaki K, Karamolegou K, Dimitriadis E, Pandis N, Karakousis CP, Tzortzatou-Stathopoulou F (2007) Desmoplastic small round cell tumor of the pleura. Pediatr Blood Cancer 49:335–338. https://doi.org/10.1002/pbc.20762

    Article  PubMed  Google Scholar 

  40. 40.

    Khalidi HS, Medeiros LJ, Battifora H (2000) Lymphohistiocytoid mesothelioma. An often misdiagnosed variant of sarcomatoid malignant mesothelioma. Am J Clin Pathol 113:649–654. https://doi.org/10.1309/7ECY-KN61-PP1M-52EB

    CAS  Article  PubMed  Google Scholar 

  41. 41.

    Kimura N, Hasegawa M, Hiroshima K (2018) SMARCB1/INI1/BAF47- deficient pleural malignant mesothelioma with rhabdoid features. Pathol Int 68:128–132. https://doi.org/10.1111/pin.12623

    CAS  Article  PubMed  Google Scholar 

  42. 42.

    Kindler HL, Ismaila N, Armato SG 3rd, Bueno R, Hesdorffer M, Jahan T, Jones CM, Miettinen M, Pass H, Rimner A, Rusch V, Sterman D, Thomas A, Hassan R (2018) Treatment of malignant pleural mesothelioma: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 36:1343–1373. https://doi.org/10.1200/JCO.2017.76.6394

    Article  PubMed  Google Scholar 

  43. 43.

    Kinoshita Y, Hamasaki M, Yoshimura M, Matsumoto S, Sato A, Tsujimura T, Ueda H, Makihata S, Kato F, Iwasaki A, Nabeshima K (2018) A combination of MTAP and BAP1 immunohistochemistry is effective for distinguishing sarcomatoid mesothelioma from fibrous pleuritis. Lung Cancer 125:198–204. https://doi.org/10.1016/j.lungcan.2018.09.019

    Article  PubMed  Google Scholar 

  44. 44.

    Kinoshita Y, Hida T, Hamasaki M, Matsumoto S, Sato A, Tsujimura T, Kawahara K, Hiroshima K, Oda Y, Nabeshima K (2018) A combination of MTAP and BAP1 immunohistochemistry in pleural effusion cytology for the diagnosis of mesothelioma. Cancer Cytopathol 126:54–63. https://doi.org/10.1002/cncy.21928

    CAS  Article  PubMed  Google Scholar 

  45. 45.

    Knoepp SM, Placido J, Fields KL, Thomas D, Roh MH (2013) The application of immunocytochemistry to direct smears in the diagnosis of effusions. Diagn Cytopathol 41:425–430. https://doi.org/10.1002/dc.22852

    Article  PubMed  Google Scholar 

  46. 46.

    Laurent E, Begueret H, Bonhomme B, Veillon R, Thumerel M, Velasco V, Brouste V, Hoppe S, Fournier M, Grellety T, MacGrogan G (2019) SOX10, GATA3, GCDFP15, androgen receptor, and mammaglobin for the differential diagnosis between triple-negative breast cancer and TTF1-negative lung adenocarcinoma. Am J Surg Pathol 43:293–302. https://doi.org/10.1097/PAS.0000000000001216

    Article  PubMed  Google Scholar 

  47. 47.

    Le Stang N, Burke L, Blaizot G, Gibbs AR, Lebailly P, Clin B, Girard N, Galateau-Salle F, Mesopath, networks E (2020) Differential diagnosis of epithelioid malignant mesothelioma with lung and breast pleural metastasis: a systematic review compared with a standardized panel of antibodies-a new proposal that may influence pathologic practice. Arch Pathol Lab Med 144:446–456. https://doi.org/10.5858/arpa.2018-0457-OA

    Article  PubMed  Google Scholar 

  48. 48.

    Mansfield AS, Symanowski JT, Peikert T (2014) Systematic review of response rates of sarcomatoid malignant pleural mesotheliomas in clinical trials. Lung Cancer 86:133–136. https://doi.org/10.1016/j.lungcan.2014.08.017

    Article  PubMed  PubMed Central  Google Scholar 

  49. 49.

    Maskell NA, Gleeson FV, Davies RJ (2003) Standard pleural biopsy versus CT-guided cutting-needle biopsy for diagnosis of malignant disease in pleural effusions: a randomised controlled trial. Lancet 361:1326–1330

    CAS  Article  Google Scholar 

  50. 50.

    Matsumoto S, Nabeshima K, Kamei T, Hiroshima K, Kawahara K, Hata S, Marukawa K, Matsuno Y, Taguchi K, Tsujimura T (2013) Morphology of 9p21 homozygous deletion-positive pleural mesothelioma cells analyzed using fluorescence in situ hybridization and virtual microscope system in effusion cytology. Cancer Cytopathol 121:415–422. https://doi.org/10.1002/cncy.21269

    Article  PubMed  Google Scholar 

  51. 51.

    McGregor SM, Dunning R, Hyjek E, Vigneswaran W, Husain AN, Krausz T (2015) BAP1 facilitates diagnostic objectivity, classification, and prognostication in malignant pleural mesothelioma. Hum Pathol 46:1670–1678. https://doi.org/10.1016/j.humpath.2015.06.024

    CAS  Article  PubMed  Google Scholar 

  52. 52.

    Metintas M, Yildirim H, Kaya T, Ak G, Dundar E, Ozkan R, Metintas S (2016) CT scan-guided Abrams’ needle pleural biopsy versus ultrasound-assisted cutting needle pleural biopsy for diagnosis in patients with pleural effusion: a randomized, controlled trial. Respiration 91:156–163. https://doi.org/10.1159/000443483

    CAS  Article  PubMed  Google Scholar 

  53. 53.

    Meyerhoff RR, Yang CF, Speicher PJ, Gulack BC, Hartwig MG, D’Amico TA, Harpole DH, Berry MF (2015) Impact of mesothelioma histologic subtype on outcomes in the Surveillance, Epidemiology, and End Results database. J Surg Res 196:23–32. https://doi.org/10.1016/j.jss.2015.01.043

    Article  PubMed  PubMed Central  Google Scholar 

  54. 54.

    Miettinen M, McCue PA, Sarlomo-Rikala M, Rys J, Czapiewski P, Wazny K, Langfort R, Waloszczyk P, Biernat W, Lasota J, Wang Z (2014) GATA3: a multispecific but potentially useful marker in surgical pathology: a systematic analysis of 2500 epithelial and nonepithelial tumors. Am J Surg Pathol 38:13–22. https://doi.org/10.1097/PAS.0b013e3182a0218f

    Article  PubMed  PubMed Central  Google Scholar 

  55. 55.

    Minami K, Jimbo N, Tanaka Y, Hokka D, Miyamoto Y, Itoh T, Maniwa Y (2020) Malignant mesothelioma in situ diagnosed by methylthioadenosine phosphorylase loss and homozygous deletion of CDKN2A: a case report. Virchows Arch 476:469–473. https://doi.org/10.1007/s00428-019-02674-x

    CAS  Article  PubMed  Google Scholar 

  56. 56.

    Mogi A, Nabeshima K, Hamasaki M, Uesugi N, Tamura K, Iwasaki A, Shirakusa T, Iwasaki H (2009) Pleural malignant mesothelioma with invasive micropapillary component and its association with pulmonary metastasis. Pathol Int 59:874–879. https://doi.org/10.1111/j.1440-1827.2009.02459.x

    Article  PubMed  Google Scholar 

  57. 57.

    Monaco S, Mehrad M, Dacic S (2018) Recent advances in the diagnosis of malignant mesothelioma: focus on approach in challenging cases and in limited tissue and cytologic samples. Adv Anat Pathol 25:24–30. https://doi.org/10.1097/PAP.0000000000000180

    Article  PubMed  Google Scholar 

  58. 58.

    Nicholson AG, Sauter JL, Nowak AK, Kindler HL, Gill RR, Remy-Jardin M, Armato SG 3rd, Fernandez-Cuesta L, Bueno R, Alcala N, Foll M, Pass H, Attanoos R, Baas P, Beasley MB, Brcic L, Butnor KJ, Chirieac LR, Churg A, Courtiol P, Dacic S, De Perrot M, Frauenfelder T, Gibbs A, Hirsch FR, Hiroshima K, Husain A, Klebe S, Lantuejoul S, Moreira A, Opitz I, Perol M, Roden A, Roggli V, Scherpereel A, Tirode F, Tazelaar H, Travis WD, Tsao MS, van Schil P, Vignaud JM, Weynand B, Lang-Lazdunski L, Cree I, Rusch VW, Girard N, Galateau-Salle F (2020) EURACAN/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach. J Thorac Oncol 15:29–49. https://doi.org/10.1016/j.jtho.2019.08.2506

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  59. 59.

    Ordonez NG (2006) Mesothelioma with rhabdoid features: an ultrastructural and immunohistochemical study of 10 cases. Mod Pathol 19:373–383. https://doi.org/10.1038/modpathol.3800543

    Article  PubMed  Google Scholar 

  60. 60.

    Ordonez NG (2012) Deciduoid mesothelioma: report of 21 cases with review of the literature. Mod Pathol 25:1481–1495. https://doi.org/10.1038/modpathol.2012.105

    Article  PubMed  Google Scholar 

  61. 61.

    Ordonez NG (2012) Pleomorphic mesothelioma: report of 10 cases. Mod Pathol 25:1011–1022. https://doi.org/10.1038/modpathol.2012.39

    Article  PubMed  Google Scholar 

  62. 62.

    Ordonez NG, Sahin AA (2014) Diagnostic utility of immunohistochemistry in distinguishing between epithelioid pleural mesotheliomas and breast carcinomas: a comparative study. Hum Pathol 45:1529–1540. https://doi.org/10.1016/j.humpath.2014.03.006

    CAS  Article  PubMed  Google Scholar 

  63. 63.

    Pelosi G, Papotti M, Righi L, Rossi G, Ferrero S, Bosari S, Calabrese F, Kern I, Maisonneuve P, Sonzogni A, Albini A, Harari S, Barbieri F, Capelletto E, Catino AM, Cavone D, De Palma A, Fusco N, Lunardi F, Maiorano E, Marzullo A, Novello S, Papanikolaou N, Pasello G, Pennella A, Pezzuto F, Punzi A, Prisciandaro E, Rea F, Rosso L, Scattone A, Serio G (2018) Pathologic grading of malignant pleural mesothelioma: an evidence-based proposal. J Thorac Oncol 13:1750–1761. https://doi.org/10.1016/j.jtho.2018.07.002

    Article  PubMed  Google Scholar 

  64. 64.

    Pillappa R, Maleszewski JJ, Sukov WR, Bedroske PP, Greipp PT, Boland JM, Yi ES, Peikert T, Aubry MC, Roden AC (2018) Loss of BAP1 expression in atypical mesothelial proliferations helps to predict malignant mesothelioma. Am J Surg Pathol 42:256–263. https://doi.org/10.1097/PAS.0000000000000976

    Article  PubMed  Google Scholar 

  65. 65.

    Rekhtman N, Montecalvo J, Chang JC, Alex D, Ptashkin RN, Ai N, Sauter JL, Kezlarian B, Jungbluth A, Desmeules P, Beras A, Bishop JA, Plodkowski AJ, Gounder MM, Schoenfeld AJ, Namakydoust A, Li BT, Rudin CM, Riely GJ, Jones DR, Ladanyi M, Travis WD (2020) SMARCA4-deficient thoracic sarcomatoid tumors represent primarily smoking-related undifferentiated carcinomas rather than primary thoracic sarcomas. J Thorac Oncol 15:231–247. https://doi.org/10.1016/j.jtho.2019.10.023

    CAS  Article  PubMed  Google Scholar 

  66. 66.

    Righi L, Duregon E, Vatrano S, Izzo S, Giorcelli J, Rondon-Lagos M, Ascoli V, Ruffini E, Ventura L, Volante M, Papotti M, Scagliotti GV (2016) BRCA1-associated protein 1 (BAP1) immunohistochemical expression as a diagnostic tool in malignant pleural mesothelioma classification: a large retrospective study. J Thorac Oncol 11:2006–2017. https://doi.org/10.1016/j.jtho.2016.06.020

    Article  PubMed  Google Scholar 

  67. 67.

    Rosen LE, Karrison T, Ananthanarayanan V, Gallan AJ, Adusumilli PS, Alchami FS, Attanoos R, Brcic L, Butnor KJ, Galateau-Salle F, Hiroshima K, Kadota K, Klampatsa A, Stang NL, Lindenmann J, Litzky LA, Marchevsky A, Medeiros F, Montero MA, Moore DA, Nabeshima K, Pavlisko EN, Roggli VL, Sauter JL, Sharma A, Sheaff M, Travis WD, Vigneswaran WT, Vrugt B, Walts AE, Tjota MY, Krausz T, Husain AN (2018) Nuclear grade and necrosis predict prognosis in malignant epithelioid pleural mesothelioma: a multi-institutional study. Mod Pathol 31:598–606. https://doi.org/10.1038/modpathol.2017.170

    Article  PubMed  Google Scholar 

  68. 68.

    Sauter JL, Graham RP, Larsen BT, Jenkins SM, Roden AC, Boland JM (2017) SMARCA4-deficient thoracic sarcoma: a distinctive clinicopathological entity with undifferentiated rhabdoid morphology and aggressive behavior. Mod Pathol 30:1422–1432. https://doi.org/10.1038/modpathol.2017.61

    CAS  Article  PubMed  Google Scholar 

  69. 69.

    Sheffield BS, Hwang HC, Lee AF, Thompson K, Rodriguez S, Tse CH, Gown AM, Churg A (2015) BAP1 immunohistochemistry and p16 FISH to separate benign from malignant mesothelial proliferations. Am J Surg Pathol 39:977–982. https://doi.org/10.1097/PAS.0000000000000394

    Article  PubMed  Google Scholar 

  70. 70.

    Sterrett GF, Whitaker D, Shilkin KB, Walters MN (1987) Fine needle aspiration cytology of malignant mesothelioma. Acta Cytol 31:185–193

    CAS  PubMed  Google Scholar 

  71. 71.

    Tozbikian GH, Zynger DL (2019) A combination of GATA3 and SOX10 is useful for the diagnosis of metastatic triple-negative breast cancer. Hum Pathol 85:221–227. https://doi.org/10.1016/j.humpath.2018.11.005

    CAS  Article  PubMed  Google Scholar 

  72. 72.

    Walts AE, Hiroshima K, McGregor SM, Wu D, Husain AN, Marchevsky AM (2016) BAP1 immunostain and CDKN2A (p16) FISH analysis: clinical applicability for the diagnosis of malignant mesothelioma in effusions. Diagn Cytopathol 44:599–606. https://doi.org/10.1002/dc.23491

    Article  PubMed  Google Scholar 

  73. 73.

    Whitaker D, Henderson DW, Shilkin KB (1992) The concept of mesothelioma in situ: implications for diagnosis and histogenesis. Semin Diagn Pathol 9:151–161

    CAS  PubMed  Google Scholar 

  74. 74.

    Wilkinson L, Coucher J, Murphy M, Joubert W, Cooper C (2018) CIC-rearranged sarcoma of the pleura: an unreported primary site, expanding the anatomical distribution of an emerging entity. Pathology 50:469–472. https://doi.org/10.1016/j.pathol.2017.11.092

    Article  PubMed  Google Scholar 

  75. 75.

    Zhang YZ, Brambilla C, Molyneaux PL, Rice A, Robertus JL, Jordan S, Lim E, Lang-Lazdunski L, Begum S, Dusmet M, Anikin V, Beddow E, Finch J, Asadi N, Popat S, Cookson WOC, Moffatt MF, Nicholson AG (2020) Utility of nuclear grading system in epithelioid malignant pleural mesothelioma in biopsy-heavy setting: an external validation study of 563 cases. Am J Surg Pathol 44:347–356. https://doi.org/10.1097/PAS.0000000000001416

    Article  PubMed  Google Scholar 

Download references

Author information

Affiliations

Authors

Contributions

MaryBeth Beasley had the idea for the article, performed the literature search and data analysis and drafted the manuscript; Francoise Gallateau-Salle performed the literature search and data analysis and critically revised the manuscript; Sanja Dacic had the idea for the article, performed the literature search and data analysis, and drafted the manuscript.

Corresponding author

Correspondence to Sanja Dacic.

Ethics declarations

Conflict of interest

Drs. Gallateau-Salle and Dacic declare no conflict of interest. Dr. Beasley declares personal fees for medicolegal work in regard to mesothelioma.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Beasley, M.B., Galateau-Salle, F. & Dacic, S. Pleural mesothelioma classification update. Virchows Arch (2021). https://doi.org/10.1007/s00428-021-03031-7

Download citation

Keywords

  • Mesothelioma
  • Pleura
  • Histologic classification